Celfex AB to engage Noah Therapeutics for Phase 2 Clinical Trial
Celfex AB is pleased to announce its engagement with Noah Therapeutics to conduct a Phase 2 clinical trial evaluating the safety and efficacy of its proprietary topical Fexofenadine formulation for the treatment of mild to moderate Atopic Dermatitis.
The Phase 2 trial will enroll patients with mild to moderate Atopic Dermatitis and evaluate the therapeutic potential of topical Fexofenadine across multiple endpoints, including EASI score improvement, itch reduction, and quality of life measures.
"This is a significant milestone for Celfex," said the company. "Partnering with Noah Therapeutics brings world-class clinical trial expertise to our development program, and we look forward to generating the clinical evidence needed to advance our topical Fexofenadine formulation toward regulatory approval."
The information in this article is for informational purposes only and does not constitute medical advice. Celfex products are under clinical development and not yet approved for commercial use.